RU2017137763A - Депо-составы для инъекций - Google Patents
Депо-составы для инъекций Download PDFInfo
- Publication number
- RU2017137763A RU2017137763A RU2017137763A RU2017137763A RU2017137763A RU 2017137763 A RU2017137763 A RU 2017137763A RU 2017137763 A RU2017137763 A RU 2017137763A RU 2017137763 A RU2017137763 A RU 2017137763A RU 2017137763 A RU2017137763 A RU 2017137763A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- paragraphs
- injection
- syringe
- subject
- Prior art date
Links
- 238000002347 injection Methods 0.000 title claims 19
- 239000007924 injection Substances 0.000 title claims 19
- 239000000203 mixture Substances 0.000 claims 26
- 238000000034 method Methods 0.000 claims 18
- 229940043355 kinase inhibitor Drugs 0.000 claims 13
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 13
- 239000002139 L01XE22 - Masitinib Substances 0.000 claims 5
- 229960004655 masitinib Drugs 0.000 claims 5
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 claims 5
- -1 pegapra Chemical compound 0.000 claims 5
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 4
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 4
- 229960000639 pazopanib Drugs 0.000 claims 4
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 4
- 229960003787 sorafenib Drugs 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 206010025421 Macule Diseases 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 230000007850 degeneration Effects 0.000 claims 3
- 206010003694 Atrophy Diseases 0.000 claims 2
- 201000004569 Blindness Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 239000011521 glass Substances 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 208000018769 loss of vision Diseases 0.000 claims 2
- 231100000864 loss of vision Toxicity 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 239000011148 porous material Substances 0.000 claims 2
- 210000001957 retinal vein Anatomy 0.000 claims 2
- 230000004393 visual impairment Effects 0.000 claims 2
- 210000004127 vitreous body Anatomy 0.000 claims 2
- SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 claims 1
- SRSGVKWWVXWSJT-ATVHPVEESA-N 5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-n-(2-pyrrolidin-1-ylethyl)-1h-pyrrole-3-carboxamide Chemical compound CC=1NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C(C)C=1C(=O)NCCN1CCCC1 SRSGVKWWVXWSJT-ATVHPVEESA-N 0.000 claims 1
- 239000003840 Bafetinib Substances 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 208000008069 Geographic Atrophy Diseases 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 claims 1
- 241000283953 Lagomorpha Species 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 239000004743 Polypropylene Substances 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 239000005464 Radotinib Substances 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- LOGJQOUIVKBFGH-UHFFFAOYSA-N SU6656 Chemical compound C1CCCC(N2)=C1C=C2C=C1C(=O)NC2=CC=C(S(=O)(=O)N(C)C)C=C21 LOGJQOUIVKBFGH-UHFFFAOYSA-N 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- 239000003819 Toceranib Substances 0.000 claims 1
- 229960003982 apatinib Drugs 0.000 claims 1
- 229950002365 bafetinib Drugs 0.000 claims 1
- ZGBAJMQHJDFTQJ-DEOSSOPVSA-N bafetinib Chemical group C1[C@@H](N(C)C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=NC=3)C(C)=CC=2)C=C1C(F)(F)F ZGBAJMQHJDFTQJ-DEOSSOPVSA-N 0.000 claims 1
- 229960003736 bosutinib Drugs 0.000 claims 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims 1
- 244000309464 bull Species 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 229960003784 lenvatinib Drugs 0.000 claims 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 claims 1
- 229950002216 linifanib Drugs 0.000 claims 1
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical group C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 claims 1
- 229960001346 nilotinib Drugs 0.000 claims 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 1
- 229920001155 polypropylene Polymers 0.000 claims 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims 1
- 239000004810 polytetrafluoroethylene Substances 0.000 claims 1
- 229960001131 ponatinib Drugs 0.000 claims 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims 1
- 229950004043 radotinib Drugs 0.000 claims 1
- DUPWHXBITIZIKZ-UHFFFAOYSA-N radotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3N=CC=NC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 DUPWHXBITIZIKZ-UHFFFAOYSA-N 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 229910001220 stainless steel Inorganic materials 0.000 claims 1
- 239000010935 stainless steel Substances 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 229960000940 tivozanib Drugs 0.000 claims 1
- 229960005048 toceranib Drugs 0.000 claims 1
- 229960000241 vandetanib Drugs 0.000 claims 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 1
- 229950000578 vatalanib Drugs 0.000 claims 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562157257P | 2015-05-05 | 2015-05-05 | |
| US62/157,257 | 2015-05-05 | ||
| PCT/US2016/030912 WO2016179357A1 (en) | 2015-05-05 | 2016-05-05 | Injectable depot formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017137763A true RU2017137763A (ru) | 2019-06-05 |
| RU2017137763A3 RU2017137763A3 (enExample) | 2019-08-21 |
Family
ID=57218334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017137763A RU2017137763A (ru) | 2015-05-05 | 2016-05-05 | Депо-составы для инъекций |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20160324836A1 (enExample) |
| EP (1) | EP3291812B1 (enExample) |
| JP (1) | JP2018520093A (enExample) |
| CN (1) | CN107530334A (enExample) |
| AU (1) | AU2016258001B2 (enExample) |
| BR (1) | BR112017023762A2 (enExample) |
| CA (1) | CA2984637A1 (enExample) |
| MX (1) | MX385405B (enExample) |
| RU (1) | RU2017137763A (enExample) |
| WO (1) | WO2016179357A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107278151A (zh) | 2014-12-15 | 2017-10-20 | 约翰霍普金斯大学 | 舒尼替尼制剂及其在治疗青光眼中的使用方法 |
| BR112018009644A2 (pt) | 2015-11-12 | 2018-11-06 | Graybug Vision Inc | micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície |
| JP7217022B2 (ja) | 2017-03-23 | 2023-02-02 | グレイバグ ビジョン インコーポレイテッド | 眼障害の治療のための薬物及び組成物 |
| CA3057875A1 (en) | 2017-05-10 | 2018-11-15 | Graybug Vision, Inc. | Extended release microparticles and suspensions thereof for medical therapy |
| CN114245737A (zh) * | 2019-06-11 | 2022-03-25 | 司斐股份有限公司 | 微乳剂组合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2156834A1 (en) * | 2008-08-08 | 2010-02-24 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye |
| CN101890018B (zh) * | 2009-05-22 | 2014-06-18 | 中国科学院化学研究所 | 一种酪氨酸蛋白激酶抑制剂及其制备方法 |
| WO2013000909A1 (en) * | 2011-06-28 | 2013-01-03 | Bayer Intellectual Property Gmbh | Topical ophthalmological pharmaceutical composition containing sorafenib |
| CN104204804B (zh) * | 2011-11-11 | 2016-09-28 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
| AR089248A1 (es) * | 2011-12-14 | 2014-08-06 | Abbvie Inc | Composiciones que contienen inhibidores de quinasas |
-
2016
- 2016-05-05 US US15/147,198 patent/US20160324836A1/en not_active Abandoned
- 2016-05-05 JP JP2017558027A patent/JP2018520093A/ja active Pending
- 2016-05-05 AU AU2016258001A patent/AU2016258001B2/en active Active
- 2016-05-05 EP EP16790066.1A patent/EP3291812B1/en active Active
- 2016-05-05 CN CN201680025439.7A patent/CN107530334A/zh active Pending
- 2016-05-05 CA CA2984637A patent/CA2984637A1/en not_active Abandoned
- 2016-05-05 WO PCT/US2016/030912 patent/WO2016179357A1/en not_active Ceased
- 2016-05-05 RU RU2017137763A patent/RU2017137763A/ru not_active Application Discontinuation
- 2016-05-05 BR BR112017023762-8A patent/BR112017023762A2/pt not_active Application Discontinuation
- 2016-05-05 MX MX2017014084A patent/MX385405B/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016258001B2 (en) | 2020-06-04 |
| WO2016179357A1 (en) | 2016-11-10 |
| EP3291812A4 (en) | 2019-01-09 |
| MX2017014084A (es) | 2018-06-20 |
| MX385405B (es) | 2025-03-18 |
| CA2984637A1 (en) | 2016-11-10 |
| US20160324836A1 (en) | 2016-11-10 |
| EP3291812B1 (en) | 2021-09-01 |
| CN107530334A (zh) | 2018-01-02 |
| BR112017023762A2 (pt) | 2018-07-31 |
| EP3291812A1 (en) | 2018-03-14 |
| AU2016258001A1 (en) | 2017-11-09 |
| JP2018520093A (ja) | 2018-07-26 |
| RU2017137763A3 (enExample) | 2019-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017137763A (ru) | Депо-составы для инъекций | |
| EA201991299A1 (ru) | Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов | |
| EP4364724A3 (en) | High concentration vegf receptor fusion protein containing formulations | |
| JP2018520093A5 (enExample) | ||
| MX383808B (es) | Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf. | |
| BR112017020948A2 (pt) | composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão | |
| MX2017003102A (es) | Formulacion para inhalacion liquida que comprende rpl554. | |
| RU2013112353A (ru) | Фосфолипидный депо-препарат | |
| JP7248836B2 (ja) | ヘテロシクリデンアセトアミド誘導体含有医薬 | |
| Morton et al. | A macrocyclic calpain inhibitor slows the development of inherited cortical cataracts in a sheep model | |
| JP6598381B2 (ja) | 角膜厚調節剤 | |
| MX2017012312A (es) | Formulacion estable para administracion parenteral de tapentadol. | |
| BR112019000897A2 (pt) | sal de adição de ácido, composição farmacêutica, uso do sal de adição de ácido ou da composição farmacêutica, e, método para prevenção, tratamento ou atenuação de um distúrbio de fibrose de tecido ou órgão. | |
| Grimaudo et al. | Parameters affecting the transscleral delivery of two positively charged proteins of comparable size | |
| CN111107838A (zh) | 用于治疗干眼症的含有瑞巴派特的新型滴眼剂组合物及其增溶和稳定化方法 | |
| PH12020551194A1 (en) | Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof | |
| MX2021011727A (es) | Composiciones y metodos para tratar enfermedades oculares. | |
| EP4326261A4 (en) | Methods and compositions for treating mydriasis, glaucoma, and other ocular conditions | |
| WO2016083767A3 (en) | Epithelial treatment | |
| Schelbergen et al. | The S100A9 inhibitor paquinimod (ABR-215757) reduces synovial activation, osteophyte formation and cartilage damage in experimental osteoarthritis | |
| RU2614691C2 (ru) | Гепатопротекторное средство | |
| AR102572A1 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf | |
| Yakubchuk et al. | Development of the pharmaceutical composition and technology of combined eye drops for glaucoma treatment | |
| Hubina-Vakulick et al. | Histological aspects in the designing of alzheimer's type dementia of vascular origin and the manifestation of the brain tissue cellular regeneration in rats | |
| AR130115A2 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210505 |